|
Name |
Carviolin
|
Molecular Formula | C16H12O6 | |
IUPAC Name* |
1,3-dihydroxy-6-(hydroxymethyl)-8-methoxyanthracene-9,10-dione
|
|
SMILES |
COC1=CC(=CC2=C1C(=O)C3=C(C2=O)C=C(C=C3O)O)CO
|
|
InChI |
InChI=1S/C16H12O6/c1-22-12-3-7(6-17)2-9-14(12)16(21)13-10(15(9)20)4-8(18)5-11(13)19/h2-5,17-19H,6H2,1H3
|
|
InChIKey |
XNMZBRJAWRIJII-UHFFFAOYSA-N
|
|
Synonyms |
carviolin; 478-35-3; 1,3-dihydroxy-6-(hydroxymethyl)-8-methoxy-9,10-anthracenedione; 1,3-DIHYDROXY-6-(HYDROXYMETHYL)-8-METHOXYANTHRACENE-9,10-DIONE; Carviolin; Roseopurpurin; CHEMBL464169; SCHEMBL16226465; DTXSID801345938; Carviolin, >=95% (LC/MS-UV); HY-N10267; ZINC14811261; BS-1466; CS-0143540; NCGC00384612-01!1,3-dihydroxy-6-(hydroxymethyl)-8-methoxyanthracene-9,10-dione
|
|
CAS | 478-35-3 | |
PubChem CID | 10040432 | |
ChEMBL ID | CHEMBL464169 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 300.26 | ALogp: | 1.8 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 104.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 22 | QED Weighted: | 0.667 |
Caco-2 Permeability: | -5.227 | MDCK Permeability: | 0.00000456 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.522 | 20% Bioavailability (F20%): | 0.538 |
30% Bioavailability (F30%): | 0.998 |
Blood-Brain-Barrier Penetration (BBB): | 0.003 | Plasma Protein Binding (PPB): | 93.65% |
Volume Distribution (VD): | 0.553 | Fu: | 10.30% |
CYP1A2-inhibitor: | 0.935 | CYP1A2-substrate: | 0.587 |
CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.056 |
CYP2C9-inhibitor: | 0.399 | CYP2C9-substrate: | 0.64 |
CYP2D6-inhibitor: | 0.121 | CYP2D6-substrate: | 0.189 |
CYP3A4-inhibitor: | 0.143 | CYP3A4-substrate: | 0.042 |
Clearance (CL): | 8.239 | Half-life (T1/2): | 0.887 |
hERG Blockers: | 0.01 | Human Hepatotoxicity (H-HT): | 0.026 |
Drug-inuced Liver Injury (DILI): | 0.37 | AMES Toxicity: | 0.44 |
Rat Oral Acute Toxicity: | 0.022 | Maximum Recommended Daily Dose: | 0.912 |
Skin Sensitization: | 0.913 | Carcinogencity: | 0.029 |
Eye Corrosion: | 0.043 | Eye Irritation: | 0.93 |
Respiratory Toxicity: | 0.777 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005602 | 1.000 | D07MGA | 0.391 | ||||
ENC000913 | 0.935 | D0N1FS | 0.330 | ||||
ENC005489 | 0.812 | D0AZ8C | 0.328 | ||||
ENC001058 | 0.773 | D04AIT | 0.311 | ||||
ENC002031 | 0.773 | D0K8KX | 0.304 | ||||
ENC000939 | 0.746 | D06GCK | 0.303 | ||||
ENC001497 | 0.739 | D0C9XJ | 0.287 | ||||
ENC003915 | 0.707 | D07VLY | 0.287 | ||||
ENC002767 | 0.694 | D01XWG | 0.273 | ||||
ENC000094 | 0.652 | D0R3JB | 0.261 |